Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITOX-REBIF: Mitoxantrone and Interferon Beta-1a in Multiple Sclerosis
NCT02937285Phase 3Completed
- Sponsor
- CHU Rennes
- Start
- Dec 2010
- Primary completion
- May 2020
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in multiple sclerosis (MS), sponsored by CHU Rennes. Started Dec 2010; status: completed.
02
Drugs
mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02937285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02937285.